198 related articles for article (PubMed ID: 20162854)
1. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy.
Moolthiya W; Yuenyao P
Asian Pac J Cancer Prev; 2009; 10(5):865-8. PubMed ID: 20162854
[TBL] [Abstract][Full Text] [Related]
2. Detection of phosphatidylserine-positive exosomes as a diagnostic marker for ovarian malignancies: a proof of concept study.
Lea J; Sharma R; Yang F; Zhu H; Ward ES; Schroit AJ
Oncotarget; 2017 Feb; 8(9):14395-14407. PubMed ID: 28122335
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses.
Tingulstad S; Hagen B; Skjeldestad FE; Onsrud M; Kiserud T; Halvorsen T; Nustad K
Br J Obstet Gynaecol; 1996 Aug; 103(8):826-31. PubMed ID: 8760716
[TBL] [Abstract][Full Text] [Related]
4. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses.
Morgante G; la Marca A; Ditto A; De Leo V
Br J Obstet Gynaecol; 1999 Jun; 106(6):524-7. PubMed ID: 10426607
[TBL] [Abstract][Full Text] [Related]
5. The risk of malignancy index in discrimination of adnexal masses.
Ulusoy S; Akbayir O; Numanoglu C; Ulusoy N; Odabas E; Gulkilik A
Int J Gynaecol Obstet; 2007 Mar; 96(3):186-91. PubMed ID: 17280665
[TBL] [Abstract][Full Text] [Related]
6. Comparison of risk of malignancy index (RMI), CA125, CA 19-9, ultrasound score, and menopausal status in borderline ovarian tumor.
Alanbay I; Akturk E; Coksuer H; Ercan M; Karaşahin E; Dede M; Yenen MC; Ozan H; Baser I
Gynecol Endocrinol; 2012 Jun; 28(6):478-82. PubMed ID: 22122561
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum 8-OHdG is associated with poor prognosis in epithelial ovarian cancer.
Pylväs M; Puistola U; Laatio L; Kauppila S; Karihtala P
Anticancer Res; 2011 Apr; 31(4):1411-5. PubMed ID: 21508394
[TBL] [Abstract][Full Text] [Related]
8. LyGDI is a promising biomarker for ovarian cancer.
Zhen H; Yang S; Wu H; Wang S; Lv J; Ma L; Zhang X
Int J Gynecol Cancer; 2010 Apr; 20(3):316-22. PubMed ID: 20375790
[TBL] [Abstract][Full Text] [Related]
9. Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer.
Simmons AR; Fourkala EO; Gentry-Maharaj A; Ryan A; Sutton MN; Baggerly K; Zheng H; Lu KH; Jacobs I; Skates S; Menon U; Bast RC
Cancer Prev Res (Phila); 2019 Jun; 12(6):391-400. PubMed ID: 30967390
[TBL] [Abstract][Full Text] [Related]
10. Risk of malignancy index in the preoperative evaluation of pelvic masses.
Obeidat BR; Amarin ZO; Latimer JA; Crawford RA
Int J Gynaecol Obstet; 2004 Jun; 85(3):255-8. PubMed ID: 15145261
[TBL] [Abstract][Full Text] [Related]
11. Prognostic and predictive relevance of CA-125 at primary surgery of ovarian cancer.
Mury D; Woelber L; Jung S; Eulenburg C; Choschzick M; Witzel I; Schwarz J; Jaenicke F; Mahner S
J Cancer Res Clin Oncol; 2011 Jul; 137(7):1131-7. PubMed ID: 21344262
[TBL] [Abstract][Full Text] [Related]
12. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients.
Li QL; Wang CJ; Qi P; Zhang YX
Clin Transl Oncol; 2017 Oct; 19(10):1260-1267. PubMed ID: 28444641
[TBL] [Abstract][Full Text] [Related]
13. A risk of malignancy index in preoperative diagnosis of ovarian cancer.
Ma S; Shen K; Lang J
Chin Med J (Engl); 2003 Mar; 116(3):396-9. PubMed ID: 12781045
[TBL] [Abstract][Full Text] [Related]
14. [Effect of a risk of malignancy index in preoperative diagnosis of ovarian cancer].
Ma S; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2001 Mar; 36(3):162-4. PubMed ID: 11783394
[TBL] [Abstract][Full Text] [Related]
15. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
16. Ovarian fibroma/fibrothecoma: retrospective cohort study shows limited value of risk of malignancy index score.
Numanoglu C; Kuru O; Sakinci M; Akbayır O; Ulker V
Aust N Z J Obstet Gynaecol; 2013 Jun; 53(3):287-92. PubMed ID: 23611791
[TBL] [Abstract][Full Text] [Related]
17. Risk of malignancy index in preoperative evaluation of pelvic masses.
Ashrafgangooei T; Rezaeezadeh M
Asian Pac J Cancer Prev; 2011; 12(7):1727-30. PubMed ID: 22126553
[TBL] [Abstract][Full Text] [Related]
18. Comparison of pelvic masses score (PMS) and Risk of Malignancy Index (RMI 3) in the evaluation of pelvic masses.
Rossi A; Forzano L; Romanello I; Ambrosini G; Iuri V; Marchesoni D
Eur J Gynaecol Oncol; 2014; 35(4):421-4. PubMed ID: 25118484
[TBL] [Abstract][Full Text] [Related]
19. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses.
van den Akker PA; Zusterzeel PL; Aalders AL; Snijders MP; Samlal RA; Vollebergh JH; Kluivers KB; Massuger LF
Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):422-5. PubMed ID: 21824712
[TBL] [Abstract][Full Text] [Related]
20. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
